|
Novacyt SA on Wednesday said it completed a period of restructuring and integration as it looked forward to ‘driving innovation further’. The Paris-based biotechnology group focused on clinical diagnostics said it expects to report 2025 revenue of £20.0 million, up 2.0% from £19.6 million in 2024 and in line with market expectations of £19.8 million. Underlying revenue was up by around 4%, or 5% on a constant currency basis, excluding the impact of the Taiwan service laboratory divestment. Novacyt added that it expects to meet market expectations for an adjusted loss before interest, tax, depreciation and amortisation of £8.5 million for 2025, lower than £9.1 million in 2024. The debt-free company’s cash balance was £19.2 million as at December 31, above market expectations of £18.8 million, but down 19% from £23.8 million at June 30. It was 37% lower than the £30.5 million it had reported for December 31, 2024. Chief Executive Officer Lyn Rees said: ‘With the period of restructuring and integration completed, and the successful derisked and stabilised business formed, we committed as a board to deliver top line growth. We’re therefore pleased to have delivered year on year revenue growth in line with market expectations. It’s also pleasing to report two consecutive periods of half-year growth underpinned by an upward trajectory of revenue growth. ‘These results prove the strong foundation we have created as a group, and we look forward to driving innovation further as we continue to execute and deliver on our plans.’ The company said: ‘Beta testing is underway with international key opinion leaders in the field of precision medicine for Yourgene’s Insight DPYD assay, the enhanced DPYD test which helps identify cancer patients at risk of suffering a severe and potentially life-threatening reaction to common chemotherapy. This Beta testing has commenced in good time, ahead of the product launch expected in H1 2026.’ According to the National Health Service, DPYD is a gene that produces an enzyme called dihydropyrimidine dehydrogenase, known as DPD. The DPD enzyme helps the body to break down some types of chemotherapy. Novacyt expects to release 2025 results in April. Novacyt shares were down 3.3% to 33.11 pence each on Wednesday afternoon in London. In Paris, they were down 0.3% at 39 euro cents. Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
